Vyluma, Inc. announced that the National Medical Products Administration (NMPA) of China has accepted the drug application from Zhaoke Ophthalmology Limited for NVK002 (low-dose atropine 0.01%) for the treatment of myopia progression in children. This acceptance marks a crucial step toward introducing a new therapeutic option for managing pediatric myopia in China, where rates of the condition are among the highest in the world.
NVK002 is a proprietary, investigational, preservative-free eye drop developed by Vyluma and licensed to Zhaoke. It is designed for nightly administration in pediatric patients.
Clinical Trial Data
The drug application is supported by data from two Phase III clinical trials conducted by Zhaoke in China. The first trial, Mini-CHAMP, involved 526 patients across 16 centers and successfully met its primary efficacy endpoint, demonstrating statistically significant and clinically meaningful differences compared to placebo. The trial also reported strong safety, efficacy, and high patient tolerance.
The second Phase III trial, China CHAMP, enrolled 777 patients across 18 centers. Top-line results indicated significant efficacy and a favorable safety profile for NVK002, further supporting its potential as a treatment for myopia progression.
Global Regulatory Status
With the NMPA's acceptance, NVK002 is now under regulatory review in three major global markets: the United States, the European Union, and China. This broad regulatory engagement underscores Vyluma's commitment to addressing the global pediatric myopia epidemic.
Executive Commentary
George Zorich, Chairman and CEO of Nevakar, Inc., and acting President of Vyluma, Inc., stated, "NMPA acceptance of the drug application for NVK002 is a significant milestone for Vyluma and underscores our commitment to addressing the global pediatric myopia epidemic. China is home to one of the highest rates of pediatric myopia in the world, making this approval process critical for ensuring access to an innovative treatment that could dramatically impact the vision and quality of life for millions of children later in life. This acceptance is a testament to our dedication to advancing effective, science-based solutions for pediatric eye health worldwide."
